StockTipsArenaBeta

BUY Aurobindo Pharma — Ruchit Jain, Motilal Oswal

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byRuchit Jain, Motilal OswalHorizon: NA (inferred 1–3 months)24 Sept 2026via Business Today

Entry₹1,734Inferred
Target₹1,800
Total upside +3.81% (call closed)
Stop loss₹1,680-3.11% risk
Exit₹1,68030 Sept 2026, 12:09 pm
Stop-loss hit-3.11%
Follow Ruchit Jain for new calls(41% target hit, 34 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 1 active Short-term call on AUROPHARMASee 84 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Sept 2026
16 supporting4 neutral3 opposing
Supports the BUY call (16)

Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong

NewsGoogle News·22 Sept · 1w ago

(opens in new tab)

6 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·21 Sept · 1w ago

Aurobindo Pharma stock edges higher as US tariff risks and FDA approvals shape outlook

NewsGoogle News·19 Sept · 1w ago

(opens in new tab)

Aurobindo Pharma Share Price rises: stock analysis note

NewsGoogle News·17 Sept · 2w ago

(opens in new tab)

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

NewsEt-Markets·16 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (4)

Aurobindo Pharma arm Apitoria incorporates Avogent Lifesciences as subsidiary

NewsGoogle News·1 Sept · 4w ago

(opens in new tab)

Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.

BSE · Company Update·1 Sept · 4w ago

(opens in new tab)
Weighs against the BUY call (3)

1 other SEBI-registered advisor has an active short-term SELL call on this stock

Advisor consensus · same horizon·6 Aug · 2mo ago

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·27 Jul · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Ruchit Jain, Motilal Oswal

Every call and its outcome